Financial Position - As of September 30, 2024, Alumis had cash and cash equivalents and marketable securities of 361.9million,expectedtofundoperationsinto2026[9]−Totalcurrentassetsincreasedsignificantlyto377,347,000 in 2024 from 53,357,000in2023,representingagrowthof608213,417,000 in 2024, up from 45,996,000in2023,markinganincreaseof364412,559,000 in 2024, compared to 89,612,000in2023,reflectingagrowthof36033,515,000 in 2024 from 20,871,000in2023,whichisanincreaseof60348,389,000 in 2024, up from a deficit of 339,260,000in2023,indicatingapositiveshiftinequity[16]−Totalliabilitiesincreasedto64,170,000 in 2024 from 53,502,000in2023,whichisanincreaseof2087.8 million, a significant increase from 37.8millioninQ32023,drivenbya23.0 million clinical milestone payment and increased trial costs[10] - A-005 Phase 1 clinical study data is expected by year-end 2024, with plans to initiate a Phase 2 trial in multiple sclerosis in 2025[8] - ESK-001 demonstrated a primary endpoint achievement of PASI 75 in 93% of patients at the top dose of 40 mg twice daily in the Phase 2 study[3] - The Phase 3 ONWARD program for ESK-001 in moderate-to-severe plaque psoriasis includes two parallel 24-week trials, with topline results anticipated in the first half of 2026[5] - The 40 mg twice daily dose of ESK-001 achieved maximal target inhibition, leading to the highest response rates and significant improvements in patients' quality of life[4] - Research and development accrued expenses rose to 18,140,000in2024,comparedto10,946,000 in 2023, an increase of 66%[16] Operating Expenses - General and administrative expenses for Q3 2024 were 10.6million,upfrom6.0 million in Q3 2023, primarily due to personnel-related expenses[11] - Total operating expenses for Q3 2024 were 98.4million,comparedto43.8 million for the same period in 2023[15] Net Loss and Income - Net loss for Q3 2024 was 93.1million,comparedtoanetlossof43.4 million for the same period in 2023[12] - Interest income for Q3 2024 was 5.3million,comparedto951,000 in Q3 2023, reflecting increased cash reserves[15] Accounts and Capital - Accounts payable increased to 6,444,000in2024from1,118,000 in 2023, representing a growth of 478%[16] - Additional paid-in-capital surged to 912,037,000in2024,upfrom25,055,000 in 2023, a remarkable increase of 3541%[16] - The accumulated deficit widened to (563,792,000)in2024from(364,318,000) in 2023, indicating a deeper financial loss[16]
